Will Palvella Therapeutics stock go up?

According to Danelfin AI, Palvella Therapeutics has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (52.42%) is +1.60% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Palvella Therapeutics stock?

The Palvella Therapeutics target price is $146.79 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Palvella Therapeutics stock right now?

Palvella Therapeutics has today a Hold rating (AI Score 5/10), according to Danelfin AI. Its probability of beating the market in 3 months (52.42%) is +1.60% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Palvella Therapeutics stock is a good buy .

Is Palvella Therapeutics undervalued right now?

Based on analysts, the average price target downside for Palvella Therapeutics is 0.00% (1Y). According to Danelfin AI, Palvella Therapeutics has today an AI Score of 5/10 (Hold Rating).

What was the price range of Palvella Therapeutics stock over the past 12 months?

The Palvella Therapeutics stock price range over the past 12 months has been $20.62 - $154.84.

What is going on with Palvella Therapeutics stock in the last 3 months?

The Palvella Therapeutics stock performance in the last quarter has been +21.93%.

Does Palvella Therapeutics offer dividend payments?

No, Palvella Therapeutics does not currently pay dividends.

What is the current market capitalization of Palvella Therapeutics?

Palvella Therapeutics's market cap is $2.1B, as of 2026-07-03 08:00.

Palvella Therapeutics Inc (PVLA) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

PVLA AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Valuation+6.01%
How the stock is priced relative to its fundamentals
Earnings Quality+3.40%
Stability and reliability of reported earnings
Growth+1.51%
Expected pace of revenue and earnings expansion
Size & Liquidity+1.27%
Company size and trading liquidity
Sentiment+0.91%
How analysts and the market view the stock

Volatility-6.22%
How much the stock price tends to fluctuate
Momentum-5.29%
Direction and strength of recent price movements

PVLA probability advantage of beating the market (3M):

+1.60%

AI Score

Hold

Palvella Therapeutics (PVLA) has an AI Score of 5/10 (Hold) because, according to an overall analysis, it has a probability advantage of +1.60% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of PVLA (52.42%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
PVLA probability advantage of beating the market (3M)+1.60%
PVLA probability of beating the market (3M)52.42%

PVLA probability advantage of beating the market (3M): +1.60%

The AI-powered overall analysis of Palvella Therapeutics (PVLA) is based on the 26 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of PVLA:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Operating Cash Flow (Qtr Discrete)	-10.86		+5.22%
Technical	Chart Pattern (120d)	figure_122	N/A	-4.15%
Technical	Chart Pattern (252d)	figure_59	N/A	+3.23%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+2.99%
Technical	ATR (180d Volatility)	6.02		-2.87%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-2.63%
Technical	Maximum Volatility	7.35%		-2.11%
Technical	Distance from KAMA (20d)	0.15%		-1.82%
Fundamental	Sloan Ratio	0.19		-1.81%
Technical	Technicals Impact (Long Tail)	-	N/A	+1.74%
Fundamental	Upgrade to unlock			+1.66%
Sentiment	Upgrade to unlock			+1.51%
Technical	Upgrade to unlock			-1.50%
Sentiment	Upgrade to unlock			+1.47%
Sentiment	Upgrade to unlock			+1.43%

Rest of Alpha Signals: -1.19%

PVLA probability advantage of beating the market (3M)Total:+1.60%
PVLA AI Score

Significant changes Vs previous day

PVLA Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$146.79
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

PVLA Proven Hold Signal & Price Forecast

This is the price chart for PVLA from January 2, 2026 until today. The chart indicates, in yellow, the 73 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

PVLA Average Past Performance & Win Rate

Three months after its 462 Hold signals since July 2026, PVLA had an average performance of xxxxxxx and a xxxxxx Win rate (positive performance).

462 Past PVLA Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+25.77%
Average Alpha				+11.44%
Win Rate (% Positive Perf.)				47.41%
% Positive Alpha				30.68%

PVLA Frequently Asked Questions

Will Palvella Therapeutics stock go up?
According to Danelfin AI, Palvella Therapeutics has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (52.42%) is +1.60% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Palvella Therapeutics stock?
Is it a good time to buy, sell, or hold Palvella Therapeutics stock right now?
Is Palvella Therapeutics undervalued right now?
What was the price range of Palvella Therapeutics stock over the past 12 months?
What is going on with Palvella Therapeutics stock in the last 3 months?
Does Palvella Therapeutics offer dividend payments?
What is the current market capitalization of Palvella Therapeutics?

Palvella Therapeutics Inc Company Profile

Palvella Therapeutics Inc (PVLA) is a biopharmaceutical company dedicated to developing and commercializing novel therapies for serious, rare genetic skin diseases. It focuses on addressing dermatological conditions that currently have limited or no approved treatment options, aiming to fulfill significant unmet medical needs. The company's research and development efforts concentrate on advancing a pipeline of drug candidates designed to target the root causes of these debilitating disorders.

The company's scientific approach centers on a deep understanding of the underlying genetic and molecular mechanisms driving these specific skin disorders. It leverages this biological insight to design and develop targeted therapeutic agents. Palvella Therapeutics strives to create disease-modifying treatments that offer more than symptomatic relief, aiming to significantly improve the quality of life for affected patients. This involves rigorous preclinical research and subsequent progression through various stages of clinical development.

A primary area of focus for Palvella Therapeutics is pachyonychia congenita (PC), a rare, inherited disorder characterized by painful skin lesions, thickened nails, and other dermatological manifestations. Its lead investigational product candidate, PTX-022, is a small molecule designed to modulate specific cellular pathways involved in PC's pathogenesis. The company is actively engaged in clinical development programs to evaluate the safety and efficacy of PTX-022, working towards potential regulatory approvals.

Beyond pachyonychia congenita, Palvella Therapeutics maintains a pipeline that includes other early-stage programs targeting additional rare dermatological conditions. These programs aim to expand its portfolio of potential treatments for underserved patient populations. The company collaborates with patient advocacy groups, academic institutions, and medical communities to better understand patient needs and accelerate the development of its innovative drug candidates.

Palvella Therapeutics primarily serves patients suffering from rare genetic skin diseases and the specialized healthcare providers who manage these complex conditions. Its revenue model is based on future product sales and potential strategic partnerships or licensing agreements for its therapeutic candidates. The company intends to employ a direct sales force to engage healthcare professionals and operates with a global commercialization strategy.

Sector:
Country:United States
Industry:
Address:353 W. Lancaster Avenue, Suite 200, Wayne
Employees:29
Website:palvellatx.com

Pros

Orphan drug regulatory exclusivity and incentives

High pricing power in unmet medical need indications

Efficient commercialization to targeted patient populations

Patient advocacy network for disease awareness and support

Potential for expedited regulatory review pathways

Cons

Limited addressable patient population size

High clinical development failure rates for novel therapies

Intense competition for rare disease market share

Payer scrutiny on high-cost specialty drug reimbursement

Clinical trial recruitment challenges for rare diseases

PVLA Stock AI Analysis